Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Therapeutics|October 10, 2024
Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid LeukemiaRichard Harrop, Daniel G Blount, Naeem Khan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal CancerMartin Scurr, Tom Pembroke, Anja Bloom, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2010
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III studyRobert J Amato, Robert E Hawkins, Howard L Kaufman, et al.JAMA Oncology|September 8, 2017
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical TrialMartin Scurr, Tom Pembroke, Anja Bloom, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanomaJeremy P Braybrooke, Andrew Slade, Gael Deplanque, et al.Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.Lancet (London, England)|January 14, 2014
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Jean Marc Gurruchaga, G Scott Ralph, et al.Pageof 4